



EDWARD HEART HOSPITAL LEADS CHICAGO AREA WITH USE OF CORPATH® SYSTEM FOR ROBOTIC-ASSISTED VASCULAR PROCEDURES

Dr. Mark Goodwin brings advanced cardiac cath lab technology to region

WALTHAM, MA – December 16, 2015 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that Edward Heart Hospital has become the first facility in the state of Illinois to perform procedures with the CorPath System, the first FDA-cleared medical device for robotically-assisted percutaneous coronary interventions (PCI).

"From our first case, we've used the CorPath System to successfully perform complex PCI," said Mark Goodwin, MD, Chief of Cardiology, Edward Heart Hospital. "Our whole team is very excited to be leaders in bringing this technology to our patients and this protection to our staff."

"With the CorPath System, the physicians at Edward Heart Hospital are able to leverage robotic precision and protection for their expanding practice and complex case load," stated David Handler, President and Chief Executive Officer of Corindus. "Edward Hospital has always been a leader in interventional cardiology procedures and technology. We are very pleased to be working with them and to have such a prestigious Chicago hospital using our technology."

Interventional procedures performed in hospital cath labs are a leading source of radiation exposure for medical personnel and have been linked to the development of cataracts, cancer, and brain and thyroid diseases. The CorPath System allows interventional cardiologists to perform the procedure away from the patient bed side and the radiation source. Seated in a radiation-protected cockpit, the physician uses digital controls to robotically advance catheters, angioplasty balloons and stents to clear the blockage in the heart and restore blood flow. Additionally, the technology provides interventional cardiologists with the ability to accurately measure relevant anatomy, which may lead to fewer stent implants.

For additional information, visit www.corindus.com, and follow @CorindusInc.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's CorPath System is the first FDA-cleared medical device to bring robotic-assisted precision to PCI procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-

looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control. Examples of such statements include statements regarding the potential benefits of our CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. More information on potential factors that could affect Corindus’ financial results is included from time to time in the “Forward Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Corindus’ periodic and current filings with the SEC, as well as those discussed under the “Risk Factors” and “Forward Looking Statements” section of Corindus’ Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on Corindus’ website at <http://www.corindus.com/about-corindus/investor-relations>. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date.

###

Media Contacts:

Corindus Vascular Robotics

Brett Prince

(508) 653-3335 ext. 231

Brett.prince@corindus.com

Yuliya Kutuzava

(203) 504-8230 ext. 131

corindus@knbpr.com

Investor Contact:

Jamar Ismail

415-513-1282

ir@corindus.com